Zafirlukast is used to prevent asthma symptoms. Zafirlukast is in a class of medications called leukotriene receptor antagonists (LTRAs). It is also being studied for use in prostate cancer
It belongs to the family of drugs called endothelin-receptor antagonists.
Information about Zafirlukast
Zafirlukast is an orally available leukotriene receptor antagonist which is widely used for the prophylaxis and chronic treatment of asthma.
Liver safety of Zafirlukast
Zafirlukast has been linked to rare, but occasionally severe cases of acute liver injury.
Mechanism of action of Zafirlukast
Zafirlukast (za" fir loo' kast) is a leukotriene receptor antagonist that binds to the CysLT1 and CysLT2 receptors, thereby interfering with inflammatory pathways that are involved in the pathogenesis of asthma and allergic rhinitis. Pretreatment with single oral doses of zafirlukast inhibits bronchoconstriction and the early-phase and part of the late-phase inflammatory reactions in asthma.
FDA approval information for Zafirlukast
Zafirlukast was approved for use in the treatment of asthma in the United States in 1996, and it continues to be widely used with more than 2 million prescriptions filled yearly. Other leukotriene receptor antagonists include montelukast and pranlukast, but only montelukast is also available in the United States.
Clinical use of Zafirlukast
Current indications include the prophylaxis and chronic treatment of asthma in adults and children (above the age of 5).
Zafirlukast is available in 10 and 20 mg tablets generically and under the brand name Accolate.
Dosage and administration for Zafirlukast
The recommended dosage of zafirlukast in adults and children >12 years is 20 mg twice daily. The recommended dose in children 5 to 11 years is 10 mg twice daily.
Side effects of Zafirlukast
Accolate® Beta-2 Adrenergic Agonists
Cost and Coupons - Zafirlukast
- GoodRx compare cost & coupons for Zafirlukast
- Find the lowest cost of Zafirlukast
- Search for Coupons for Zafirlukast
Reviews for Zafirlukast
Learn more about Zafirlukast
Latest research (Pubmed)